Invasive Pulmonary Aspergillosis in Nonimmunocompromised Hosts

Abstract

Invasive pulmonary aspergillosis (IPA) is a fungal infection that is the hallmark of severe cellular or complex immune alterations. Evidence that IPA can occur in nonimmunocompromised hosts is increasing. Actually, up to 1% of general intensive care unit (ICU) patients present positive samples with Aspergillus spp. Both colonization and invasive disease are associated with poor outcome. Unexpected IPA has also been reported in approximately 1% of critically ill patients who underwent postmortem biopsies. In nonimmunocompromised patients with acute respiratory distress syndrome (ARDS), IPA prevalence can reach up to 15% of patients in both clinical and autopsy studies. Factors associated with IPA in nonimmunocompromised critically ill hosts include short and long courses of steroids, broad antibiotic therapy, chronic obstructive pulmonary disease, ARDS, liver failure, and the severity of organ dysfunctions.

This review aims to appraise the prevalence of IPA in nonimmunocompromised hosts, address diagnostic challenges, and outcomes.

Keywords

Aspergillus - transplant - COPD - influenza - sepsis - steroids

• References

• 1 Herbrecht R, Denning DW, Patterson TF. , et al; Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347 (06) 408-415
• 2 Gerson SL, Talbot GH, Hurwitz S, Strom BL, Lusk EJ, Cassileth PA. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med 1984; 100 (03) 345-351
• 3 Soubani AO, Chandrasekar PH. The clinical spectrum of pulmonary aspergillosis. Chest 2002; 121 (06) 1988-1999
• 4 Segal BH. Aspergillosis. N Engl J Med 2009; 360 (18) 1870-1884
• 5 Blum J, Reed JC, Pizzo SV, Thompson WM. Miliary aspergillosis associated with alcoholism. AJR Am J Roentgenol 1978; 131 (04) 707-709
• 6 Hartemink KJ, Paul MA, Spijkstra JJ, Girbes ARJ, Polderman KH. Immunoparalysis as a cause for invasive aspergillosis?. Intensive Care Med 2003; 29 (11) 2068-2071
• 7 Eckerle I, Ebinger D, Gotthardt D. , et al. Invasive Aspergillus fumigatus infection after Plasmodium falciparum malaria in an immuno-competent host: case report and review of literature. Malar J 2009; 8: 167
• 8 Dominelli GS, Shaipanich T. Ulcerative tracheobronchitis due to Aspergillus. J Bronchology Interv Pulmonol 2013; 20 (04) 326-329
• 9 Tavazzi G, Via G, Marzani FC, Mojoli F. Invasive pulmonary aspergillosis after near-drowning. Lancet Infect Dis 2016; 16 (12) 1430
• 10 Moreno-González G, Ricart de Mesones A, Tazi-Mezalek R, Marron-Moya MT, Rosell A, Mañez R. Invasive pulmonary aspergillosis with disseminated infection in immunocompetent patient. Can Respir J 2016; 2016: 7984032
• 11 Meersseman W, Vandecasteele SJ, Wilmer A, Verbeken E, Peetermans WE, Van Wijngaerden E. Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med 2004; 170 (06) 621-625
• 12 Vandewoude KH, Blot SI, Depuydt P. , et al. Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients. Crit Care 2006; 10 (01) R31
• 13 Garnacho-Montero J, Amaya-Villar R, Ortiz-Leyba C. , et al. Isolation of Aspergillus spp. from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome. Crit Care 2005; 9 (03) R191-R199
• 14 Bassetti M, Mikulska M, Repetto E. , et al. Invasive pulmonary aspergillosis in intensive care units: is it a real problem?. J Hosp Infect 2010; 74 (02) 186-187
• 15 Vincent J-L, Rello J, Marshall J. , et al; EPIC II Group of Investigators. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009; 302 (21) 2323-2329
• 16 Xu N, Li S, Feng R, Wang D. The clinical monitoring of invasive aspergillosis in surgical intensive care unit during 10 years [in Chinese]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2014; 26 (09) 634-638
• 17 Vandewoude KH, Blot SI, Benoit D, Colardyn F, Vogelaers D. Invasive aspergillosis in critically ill patients: attributable mortality and excesses in length of ICU stay and ventilator dependence. J Hosp Infect 2004; 56 (04) 269-276
• 18 Tejerina E, Esteban A, Fernández-Segoviano P. , et al. Clinical diagnoses and autopsy findings: discrepancies in critically ill patients*. Crit Care Med 2012; 40 (03) 842-846
• 19 Lehrnbecher T, Frank C, Engels K, Kriener S, Groll AH, Schwabe D. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 2010; 61 (03) 259-265
• 20 Dimopoulos G, Piagnerelli M, Berré J, Salmon I, Vincent J-L. Post mortem examination in the intensive care unit: still useful?. Intensive Care Med 2004; 30 (11) 2080-2085
• 21 de Hemptinne Q, Remmelink M, Brimioulle S, Salmon I, Vincent J-L. ARDS: a clinicopathological confrontation. Chest 2009; 135 (04) 944-949
• 22 Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis 2013; 13 (03) 260-268
• 23 Boomer JS, To K, Chang KC. , et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 2011; 306 (23) 2594-2605
• 24 Copland IB, Kavanagh BP, Engelberts D, McKerlie C, Belik J, Post M. Early changes in lung gene expression due to high tidal volume. Am J Respir Crit Care Med 2003; 168 (09) 1051-1059
• 25 Park WY, Goodman RB, Steinberg KP. , et al. Cytokine balance in the lungs of patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 2001; 164 (10, Pt 1): 1896-1903
• 26 Pène F, Courtine E, Ouaaz F. , et al. Toll-like receptors 2 and 4 contribute to sepsis-induced depletion of spleen dendritic cells. Infect Immun 2009; 77 (12) 5651-5658
• 27 Camargo JF, Lobo SA, Hsu AP, Zerbe CS, Wormser GP, Holland SM. MonoMAC syndrome in a patient with a GATA2 mutation: case report and review of the literature. Clin Infect Dis 2013; 57 (05) 697-699
• 28 Hsu AP, Johnson KD, Falcone EL. , et al. GATA2 haploinsufficiency caused by mutations in a conserved intronic element leads to MonoMAC syndrome. Blood 2013; 121 (19) 3830-3837 , S1–S7
• 29 Picard C, Al-Herz W, Bousfiha A. , et al. Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015. J Clin Immunol 2015; 35 (08) 696-726
• 30 De Pauw B, Walsh TJ, Donnelly JP. , et al; European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46 (12) 1813-1821
• 31 Bulpa P, Dive A, Sibille Y. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Eur Respir J 2007; 30 (04) 782-800
• 32 Blot SI, Taccone FS, Van den Abeele A-M. , et al; AspICU Study Investigators. A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients. Am J Respir Crit Care Med 2012; 186 (01) 56-64
• 33 Huang L, He H, Jin J, Zhan Q. Is Bulpa criteria suitable for the diagnosis of probable invasive pulmonary aspergillosis in critically ill patients with chronic obstructive pulmonary disease? A comparative study with EORTC/ MSG and ICU criteria. BMC Infect Dis 2017; 17 (01) 209
• 34 Perfect JR, Cox GM, Lee JY. , et al; Mycoses Study Group. The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. Clin Infect Dis 2001; 33 (11) 1824-1833
• 35 Lugosi M, Alberti C, Zahar J-R. , et al. Aspergillus in the lower respiratory tract of immunocompetent critically ill patients. J Infect 2014; 69 (03) 284-292
• 36 Delsuc C, Cottereau A, Frealle E. , et al. Putative invasive pulmonary aspergillosis in critically ill patients with chronic obstructive pulmonary disease: a matched cohort study. Crit Care 2015; 19: 421
• 37 Barberán J, García-Pérez F-J, Villena V. , et al; working group on Infectious Diseases from the Spanish Society of Internal Medicine. Development of aspergillosis in a cohort of non-neutropenic, non-transplant patients colonised by Aspergillus spp. BMC Infect Dis 2017; 17 (01) 34
• 38 Cornillet A, Camus C, Nimubona S. , et al. Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey. Clin Infect Dis 2006; 43 (05) 577-584
• 39 Lionakis MS, Kontoyiannis DP. Glucocorticoids and invasive fungal infections. Lancet 2003; 362 (9398): 1828-1838
• 40 Diamond RD. Inhibition of monocyte-mediated damage to fungal hyphae by steroid hormones. J Infect Dis 1983; 147 (01) 160
• 41 Diamond RD, Huber E, Haudenschild CC. Mechanisms of destruction of Aspergillus fumigatus hyphae mediated by human monocytes. J Infect Dis 1983; 147 (03) 474-483
• 42 Schaffner A. Therapeutic concentrations of glucocorticoids suppress the antimicrobial activity of human macrophages without impairing their responsiveness to gamma interferon. J Clin Invest 1985; 76 (05) 1755-1764
• 43 Ng TT, Robson GD, Denning DW. Hydrocortisone-enhanced growth of Aspergillus spp.: implications for pathogenesis. Microbiology 1994; 140 (Pt 9): 2475-2479
• 44 Prodanovic H, Cracco C, Massard J. , et al. Invasive pulmonary aspergillosis in patients with decompensated cirrhosis: case series. BMC Gastroenterol 2007; 7: 2
• 45 Palmer LB, Greenberg HE, Schiff MJ. Corticosteroid treatment as a risk factor for invasive aspergillosis in patients with lung disease. Thorax 1991; 46 (01) 15-20
• 46 Ader F, Nseir S, Le Berre R. , et al. Invasive pulmonary aspergillosis in chronic obstructive pulmonary disease: an emerging fungal pathogen. Clin Microbiol Infect 2005; 11 (06) 427-429
• 47 He H, Ding L, Sun B, Li F, Zhan Q. Role of galactomannan determinations in bronchoalveolar lavage fluid samples from critically ill patients with chronic obstructive pulmonary disease for the diagnosis of invasive pulmonary aspergillosis: a prospective study. Crit Care 2012; 16 (04) R138
• 48 He H, Jiang S, Zhang L. , et al. Aspergillus tracheobronchitis in critically ill patients with chronic obstructive pulmonary diseases. Mycoses 2014; 57 (08) 473-482
• 49 Agustí C, Rañó A, Filella X. , et al. Pulmonary infiltrates in patients receiving long-term glucocorticoid treatment: etiology, prognostic factors, and associated inflammatory response. Chest 2003; 123 (02) 488-498
• 50 Patel DA, Gao X, Stephens JM, Forshag MS, Tarallo M. US hospital database analysis of invasive aspergillosis in the chronic obstructive pulmonary disease non-traditional host. J Med Econ 2011; 14 (02) 227-237
• 51 Guinea J, Torres-Narbona M, Gijón P. , et al. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome. Clin Microbiol Infect 2010; 16 (07) 870-877
• 52 Wessolossky M, Welch VL, Sen A, Babu TM, Luke DR. Invasive Aspergillus infections in hospitalized patients with chronic lung disease. Infect Drug Resist 2013; 6: 33-39
• 53 Contou D, Dorison M, Rosman J. , et al. Aspergillus-positive lower respiratory tract samples in patients with the acute respiratory distress syndrome: a 10-year retrospective study. Ann Intensive Care 2016; 6 (01) 52
• 54 Aubron C, Pilcher D, Leong T. , et al. Aspergillus sp. isolated in critically ill patients with extracorporeal membrane oxygenation support. Scand J Infect Dis 2013; 45 (09) 715-721
• 55 Rodriguez-Goncer I, Thomas S, Foden P. , et al. Invasive pulmonary aspergillosis is associated with adverse clinical outcomes in critically ill patients receiving veno-venous extracorporeal membrane oxygenation. Eur J Clin Microbiol Infect Dis 2018; 37 (07) 1251-1257
• 56 Garcia X, Mian A, Mendiratta P, Gupta P, Rycus P, Prodhan P. Aspergillus infection and extracorporeal membrane oxygenation support. J Intensive Care Med 2013; 28 (03) 178-184
• 57 Hasejima N, Yamato K, Takezawa S, Kobayashi H, Kadoyama C. Invasive pulmonary aspergillosis associated with influenza B. Respirology 2005; 10 (01) 116-119
• 58 Wauters J, Baar I, Meersseman P. , et al. Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients: a retrospective study. Intensive Care Med 2012; 38 (11) 1761-1768
• 59 Vanderbeke L, Spriet I, Breynaert C, Rijnders BJA, Verweij PE, Wauters J. Invasive pulmonary aspergillosis complicating severe influenza: epidemiology, diagnosis and treatment. Curr Opin Infect Dis 2018; 31 (06) 471-480
• 60 Schauwvlieghe AFAD, Rijnders BJA, Philips N. , et al; Dutch-Belgian Mycosis study group. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir Med 2018; 6 (10) 782-792
• 61 Huang L, Zhang N, Huang X. , et al. Invasive pulmonary aspergillosis in patients with influenza infection: a retrospective study and review of the literature. Clin Respir J 2019; 13 (04) 202-211
• 62 Zhang X, Yang M, Hu J, Zhao H, Li L. Epidemiology of invasive pulmonary aspergillosis in patients with liver failure: clinical presentation, risk factors, and outcomes. J Int Med Res 2018; 46 (02) 819-827
• 63 Acosta J, Catalan M, del Palacio-Peréz-Medel A. , et al. A prospective comparison of galactomannan in bronchoalveolar lavage fluid for the diagnosis of pulmonary invasive aspergillosis in medical patients under intensive care: comparison with the diagnostic performance of galactomannan and of (1→ 3)-β-d-glucan chromogenic assay in serum samples. Clin Microbiol Infect 2011; 17 (07) 1053-1060
• 64 He H, Ding L, Chang S, Li F, Zhan Q. Value of consecutive galactomannan determinations for the diagnosis and prognosis of invasive pulmonary aspergillosis in critically ill chronic obstructive pulmonary disease. Med Mycol 2011; 49 (04) 345-351
• 65 Meersseman W, Lagrou K, Maertens J. , et al. Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med 2008; 177 (01) 27-34
• 66 Zhou W, Li H, Zhang Y. , et al. Diagnostic value of galactomannan antigen test in serum and bronchoalveolar lavage fluid samples from patients with nonneutropenic invasive pulmonary aspergillosis. J Clin Microbiol 2017; 55 (07) 2153-2161
• 67 Torelli R, Sanguinetti M, Moody A. , et al. Diagnosis of invasive aspergillosis by a commercial real-time PCR assay for Aspergillus DNA in bronchoalveolar lavage fluid samples from high-risk patients compared to a galactomannan enzyme immunoassay. J Clin Microbiol 2011; 49 (12) 4273-4278
• 68 Rose SR, Vallabhajosyula S, Velez MG. , et al. The utility of bronchoalveolar lavage beta-D-glucan testing for the diagnosis of invasive fungal infections. J Infect 2014; 69 (03) 278-283
• 69 Eigl S, Hoenigl M, Spiess B. , et al. Galactomannan testing and Aspergillus PCR in same-day bronchoalveolar lavage and blood samples for diagnosis of invasive aspergillosis. Med Mycol 2017; 55 (05) 528-534
• 70 Schroeder M, Simon M, Katchanov J. , et al. Does galactomannan testing increase diagnostic accuracy for IPA in the ICU? A prospective observational study. Crit Care 2016; 20 (01) 139
• 71 Guegan H, Robert-Gangneux F, Camus C. , et al. Improving the diagnosis of invasive aspergillosis by the detection of Aspergillus in broncho-alveolar lavage fluid: comparison of non-culture-based assays. J Infect 2018; 76 (02) 196-205